Solutions OP Clinical Trials UK

This episode is a review of the ethical issues around involving in clinical trials participants who do not have capacity to consent. What are the challenges and safeguarding requirements for vulnerable participants? Could the safeguarding have a negative impact on participants' access to clinical trials and different treatment options? These are some of the questions addressed during the review with Lydia Ainsworth.

In this episode we are discussing with Harry Henson, the associate director of RBW Consulting, how AI will reshape the healthcare and pharma industry. Is AI making the recruitment process more efficient? Would AI make recruiters redundant? What are the risks for potential candidates being pre-screened using AI? We try to discuss all these questions in a serious but also entertaining way.

In this episode we discuss with Lydia Ainsworth the global antibiotics crisis and the reasons for this crisis. In addition, we mention some of the drug development trends and some ideas how to encourage antibiotics development.

In this episode we review why we need women to participate in clinical research with medical devices. We also cover the FDA guidance on sex-specific data collection for medical devices and its main recommendations on the study design and data collection requirements.

This episode is a review of a white paper from Aug 2026 on dose optimisation for radiotherapeutics. In addition, Lydia Ainsworth reviews the FDA guidance covering the same topic and providing FDA recommendations. The episode contains recommendations on dose selection and study design for clinical trials with radiotherapeutics.

In this episode we review with Lydia Ainsworth an article discussing ethical challenges for clinical research with implantable neural devices. The overview provides valuable insights for ethics committees, researchers and manufacturers designing informed consents and investigational plans.

This episode is dedicated to psychedelics research. It covers the recommendations from the US FDA guidance from Jul 2026 which clarifies the agency's expectations regarding the drug development and clinical trials design for psychedelics. In addition, there is an overview of the study design of a clinical trial with psilocybin used in treatment-resistant depression.

This episode covers the upcoming changes in the clinical trial regulations in Canada based on information presented by Health Canada. It also contains global trends analysis and comparison to the regulatory changes in the USA and Europe.

This episode is an overview and analysis of the discussions from the 3rd day of the 5th FDA, MHRA and Health Canada Symposium in June 2026. It covers international initiatives for harmonisation of drug safety review among different regulatory agencies, and the use and challenges of AI in pharmacovigilance. In addition, Lydia Ainsworth provides practical perspective of the challenges of collecting drug safety information in clinical trials.

Our latest podcast is dedicated to bioequivalence studies and their specific challenges. We also cover what was discussed in terms of inspection findings, cases studies and expectations by FDA and Health Canada on their recent symposium in June 2026. In addition, Lydia Ainsworth, shares with us her practical experience from site level and monitoring level on common issues with blood sample collections.